BRPI0922774A2 - Composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos. - Google Patents

Composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.

Info

Publication number
BRPI0922774A2
BRPI0922774A2 BRPI0922774A BRPI0922774A BRPI0922774A2 BR PI0922774 A2 BRPI0922774 A2 BR PI0922774A2 BR PI0922774 A BRPI0922774 A BR PI0922774A BR PI0922774 A BRPI0922774 A BR PI0922774A BR PI0922774 A2 BRPI0922774 A2 BR PI0922774A2
Authority
BR
Brazil
Prior art keywords
processes
pharmaceutical composition
obtaining
nelmefeno
chloridate
Prior art date
Application number
BRPI0922774A
Other languages
English (en)
Inventor
Lopes de Diego Heidi
Anton Martin Huber Florian
De Faveri Carla
Original Assignee
H Lundbeck As
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922774(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Biotie Therapies Corp filed Critical H Lundbeck As
Publication of BRPI0922774A2 publication Critical patent/BRPI0922774A2/pt
Publication of BRPI0922774B1 publication Critical patent/BRPI0922774B1/pt
Publication of BRPI0922774B8 publication Critical patent/BRPI0922774B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composto Cloridrato de Nelmefeno Di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos. A presente invenção se refere ao cloridrato de nalmefeno di-hidratado, aos processos de manufatura de cloridrato de nalmefeno di-hidratado, a uma composição farmacêutica compreendendo cloridratro de nalmefeno di-hidratado e a um método de tratamento compreendendo administrar cloridrato de nalmefeno di-hidratado.
BRPI0922774A 2008-12-05 2009-12-04 composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos. BRPI0922774B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05
DKPA200801729 2008-12-05
PCT/DK2009/050320 WO2010063292A1 (en) 2008-12-05 2009-12-04 Nalmefene hydrochloride dihydrate

Publications (3)

Publication Number Publication Date
BRPI0922774A2 true BRPI0922774A2 (pt) 2017-07-11
BRPI0922774B1 BRPI0922774B1 (pt) 2020-10-13
BRPI0922774B8 BRPI0922774B8 (pt) 2021-05-25

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922774A BRPI0922774B8 (pt) 2008-12-05 2009-12-04 composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.

Country Status (30)

Country Link
US (2) US8530495B2 (pt)
EP (2) EP2441766B1 (pt)
JP (3) JP6055183B2 (pt)
KR (2) KR20170008893A (pt)
CN (2) CN102325778B (pt)
AR (1) AR074507A1 (pt)
AT (1) ATE546453T1 (pt)
AU (1) AU2009321898B2 (pt)
BR (1) BRPI0922774B8 (pt)
CA (1) CA2744932C (pt)
CL (1) CL2011001331A1 (pt)
CO (1) CO6362012A2 (pt)
CY (2) CY1112643T1 (pt)
DK (2) DK2300479T3 (pt)
EA (1) EA018948B1 (pt)
ES (2) ES2488165T3 (pt)
HR (2) HRP20120247T1 (pt)
IL (1) IL213112A (pt)
MX (1) MX2011005865A (pt)
MY (1) MY149028A (pt)
NZ (1) NZ593874A (pt)
PL (2) PL2300479T3 (pt)
PT (2) PT2441766E (pt)
RS (2) RS52255B (pt)
SG (1) SG171910A1 (pt)
SI (2) SI2441766T1 (pt)
SM (2) SMT201200014B (pt)
TW (1) TWI465450B (pt)
UA (1) UA102128C2 (pt)
WO (1) WO2010063292A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
AR090916A1 (es) 2012-05-03 2014-12-17 Lundbeck & Co As H Metodo para la fabricacion de naltrexona
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
PL1708690T3 (pl) * 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
EP2137189B1 (en) * 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US8399475B2 (en) * 2007-04-12 2013-03-19 Mallinckrodt Llc Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
EA201170753A1 (ru) 2011-12-30
PL2300479T3 (pl) 2012-06-29
HRP20120247T1 (hr) 2012-05-31
BRPI0922774B8 (pt) 2021-05-25
ATE546453T1 (de) 2012-03-15
US8754217B2 (en) 2014-06-17
CL2011001331A1 (es) 2011-08-26
MX2011005865A (es) 2011-09-06
US8530495B2 (en) 2013-09-10
EP2441766B1 (en) 2014-06-25
EA018948B1 (ru) 2013-11-29
CA2744932A1 (en) 2010-06-10
KR20170008893A (ko) 2017-01-24
RS53415B (sr) 2014-12-31
SI2441766T1 (sl) 2014-12-31
DK2441766T3 (da) 2014-07-21
JP2017025079A (ja) 2017-02-02
CO6362012A2 (es) 2012-01-20
CY1112643T1 (el) 2016-02-10
PT2300479E (pt) 2012-04-10
EP2300479A1 (en) 2011-03-30
JP6591944B2 (ja) 2019-10-16
EP2300479B1 (en) 2012-02-22
CY1115381T1 (el) 2017-01-04
JP2015134785A (ja) 2015-07-27
CN102325778A (zh) 2012-01-18
DK2300479T3 (da) 2012-03-26
EP2441766A1 (en) 2012-04-18
PL2441766T3 (pl) 2014-09-30
BRPI0922774B1 (pt) 2020-10-13
NZ593874A (en) 2013-02-22
IL213112A (en) 2013-06-27
TW201022273A (en) 2010-06-16
MY149028A (en) 2013-06-28
ES2380297T3 (es) 2012-05-10
AR074507A1 (es) 2011-01-19
AU2009321898A1 (en) 2011-07-14
ES2488165T3 (es) 2014-08-26
SI2300479T1 (sl) 2012-07-31
JP6055183B2 (ja) 2016-12-27
PT2441766E (pt) 2014-08-05
JP6591759B2 (ja) 2019-10-16
US20130338365A1 (en) 2013-12-19
RS52255B (sr) 2012-10-31
JP2012510954A (ja) 2012-05-17
CN104211707B (zh) 2017-04-12
SG171910A1 (en) 2011-07-28
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
KR20110089333A (ko) 2011-08-05
UA102128C2 (en) 2013-06-10
SMT201400113B (it) 2014-11-10
SMT201200014B (it) 2012-07-10
CN102325778B (zh) 2014-08-13
HRP20140648T1 (hr) 2014-09-26
WO2010063292A1 (en) 2010-06-10
US20110251228A1 (en) 2011-10-13
AU2009321898B2 (en) 2014-10-02
TWI465450B (zh) 2014-12-21
IL213112A0 (en) 2011-07-31
HK1205108A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
BRPI0922774A2 (pt) Composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
EP2569483A4 (en) METHOD FOR PRODUCING A COMPOSITION WITH FIBRILLATED CELLULOSE AND COMPOSITION
TWI449540B (en) Process for the production of an abuse-proofed dosage form
EP2100967A4 (en) METHOD FOR PRODUCING LACTO-N-BIOSE I OR GALACTO-N-BIOSE
EP2559709A4 (en) METHOD FOR PRODUCING A MODIFIED CONJUGATED DIENPOLYMER, MODIFIED CONJUGATED DIENPOLYMER AND COMPOSITION OF THE MODIFIED CONJUGATED DIENPOLYMER
EP1984561A4 (en) METHOD FOR PRODUCING MICROFIBRILLED CELLULOSE
ITMI20071260A1 (it) Procedimento di produzione di forme per la fabbricazione di calzature
EP2041778A4 (en) METHOD FOR PRODUCING SEGMENTED CHIPS
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EP2569381A4 (en) COMPOSITION WITH MICROFIBRILLED CELLULOSE AND PROCESS FOR PREPARING THIS COMPOSITION
EP2484701A4 (en) METHOD FOR PRODUCING A MODIFIED CONJUGATED DIENPOLYMER, MODIFIED CONJUGATE DIENPOLYMER, AND COMPOSITION COMPRISING THE MODIFIED CONJUGATED DIENPOLYMER
WO2009023434A3 (en) Method for stabilizing phenylephrine
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
EP2077257A4 (en) SEMICONDUCTOR CERAMIC COMPOSITION AND MANUFACTURING METHOD THEREFOR
BRPI0718565A2 (pt) Forma de dosagem sólida, e, método de produção de uma forma de dosagem sólida.
EP2412386A4 (en) ADHESIVE COMPOSITION, SOLIDS PRESENTATIVE AND MANUFACTURING METHOD THEREFOR
CY1113641T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar
IT1394673B1 (it) Metodo per la produzione di laterizi, prodotto intermedio e laterizio
EP2083003A4 (en) PROCESS FOR THE PREPARATION OF 1,1,1,3,3-PENTACHLORBUTANE
EP1930006A4 (en) METHOD FOR PRODUCING A CHINOLONE-CONTAINING LYOPHILIZED PREPARATION
WO2011003603A3 (de) Zusammensetzung für die tablettenherstellung und verfahren zu deren herstellung
IT1395043B1 (it) Metodo e macchina per la produzione contemporanea di almeno due bachi di filtro per sigarette.
FR2919190B1 (fr) Procede de preparation de compresse de cellulose oxydee.
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.